Related Experiment Video
Updated: Mar 16, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
3.6K
Rethinking biologics in lupus nephritis
1Cedars-Sinai Health System - Rheumatology, USA swamy.venuturupalli@gmail.com.
Lupus
|August 7, 2016
Summary
Lupus nephritis (LN) is a severe kidney complication of systemic lupus erythematosus. Despite new treatments, biologics have not yet fulfilled their promise in clinical trials for LN patients.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE).
- Despite treatment advances, LN often progresses to end-stage renal disease.
- Biologics offer promise but have yet to be fully realized in LN treatment.
Purpose of the Study:
- To review the current status of biologic therapies in lupus nephritis clinical trials.
- To analyze the lessons learned from past trials.
- To inform future research directions for effective LN therapies.
Main Methods:
- Review of published clinical trials involving biologic agents for lupus nephritis.
- Analysis of trial outcomes, patient responses, and adverse events.
- Synthesis of data to identify key challenges and opportunities.
Main Results:
- Several biologic agents have been investigated in LN clinical trials.
- The efficacy and safety profiles of biologics in LN remain variable.
- Consistent success in achieving long-term remission has been limited.
Conclusions:
- Biologics hold potential for treating lupus nephritis, but challenges remain.
- Experience from initial trials is crucial for designing future studies.
- Further research is needed to optimize biologic therapy and find a cure for LN.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
344
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
344
01:29Inflammatory Bowel Disease IV: Pharmacological Management
899
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
899
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
702
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
702
01:26Nephrotic Syndrome II : Assessment and Medical Management
295
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
295
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
639
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
639
01:16Drug Biotransformation: Overview
4.1K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.1K